Proxy Pharma SRL
1.8 FTEThe score of Proxy Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -45 % Total assets 0 % Headcount (avg FTE) +29 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Proxy Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 52,432 € | ||||
| Equity | 21,794 € | ||||
| Cash | 220,595 € | ||||
| EBITDA | 151,053 € | ||||
| Total assets | 752,890 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 16 Jun 2026
- Year ended 31 Dec 2024filed on 01 Jul 2025
- Year ended 31 Dec 2023filed on 28 Jun 2024
- Year ended 31 Dec 2022filed on 30 Jun 2023
- Year ended 31 Dec 2021filed on 07 Jul 2022
Proxy Pharma's financial analysis
- Solvency2.9%sector median: 41.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Proxy Pharma
Proxy Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0673.992.721
- VAT number
- BE0673992721
- Peppol
- Registered · 0208:0673992721 · as of 09 Nov 2026
- Legal form
- SRL
- Incorporated
- 07 Apr 2017
- Registered office
- 1320 Beauvechain
- Size
- Micro · 1.8 FTE
- Latest accounts
- 2025 · filed on 16 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Proxy Pharma (SRL) has been based in Beauvechain since 2017, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 52,432 € and equity of 21,794 €; its revenue is not published. With 1.8 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 2.9%, below the median of its sector (41.5%).
Companies similar to Proxy Pharma
Companies in the same business, of comparable size and area, outside its group.
- Sdsphar Retail sale of pharmaceutical products Saint-Josse-ten-Noode · balance sheet 740,622 €
- Apotheek Beekstraat Retail sale of pharmaceutical products Roeselare · balance sheet 752,161 €
- Pharmacie Neujean Retail sale of pharmaceutical products Liège · balance sheet 749,360 €
- Depasse - Schonne Pharmacie Retail sale of pharmaceutical products Éghezée · balance sheet 747,279 €
- Pharma Foch Retail sale of pharmaceutical products Montigny-le-Tilleul · balance sheet 758,621 €
- Mariec.C-Pharma Retail sale of pharmaceutical products Seneffe · balance sheet 759,407 €
- Kabbeek Farma Retail sale of pharmaceutical products Tienen · balance sheet 763,791 €
- Beirnaert-Delagaye Retail sale of pharmaceutical products Ghent · balance sheet 766,047 €
Frequently asked questions about Proxy Pharma
What is the revenue of Proxy Pharma?
Proxy Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Proxy Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0673992721 for Proxy Pharma, if the company is VAT-registered. Its company number (CBE) is 0673.992.721.
Where is the registered office of Proxy Pharma?
According to the CBE register, the registered office of Proxy Pharma is in 1320 Beauvechain.
What is the equity of Proxy Pharma?
At the close of the 2025 financial year, the equity of Proxy Pharma amounts to 21,794 €, a solvency of 2.9% of total assets.
How many people work at Proxy Pharma?
1.8 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Proxy Pharma?
The register lists 1 active mandates at Proxy Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Proxy Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →